Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients ...

AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to gather even more momentum after claiming FDA approval in chronic kidney disease (CKD).

AstraZeneca now has 16 blockbuster medicines in its portfolio with sales (product sales and alliance revenues) exceeding $1 billion, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza ...

AstraZeneca boasts a remarkably healthy drug ... That topline growth was fueled by a 21% growth rate in Farxiga revenue to $1.94 billion during the quarter. This was made possible by continued ...

and dapagliflozin (Farxiga; AstraZeneca). Amazingly, said Perera, medical therapy has evolved further since the publication of the REVIVED-BCIS2 trial results 30 months ago. “I think the clinical ...

We forecast revenue declines to begin in 2026 for Farxiga and 2032 for Tagrisso. We estimate a cost of capital of 7.1%, which is consistent with those of pharmaceutical peers. We view AstraZeneca ...

AstraZeneca missed fourth-quarter estimates for earnings but beat the same for sales. Revenues increased across all segments, with sales of most of the key drugs, including Tagrisso, Fasenra, Farxiga, ...